CA2654408C - Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance - Google Patents
Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance Download PDFInfo
- Publication number
- CA2654408C CA2654408C CA2654408A CA2654408A CA2654408C CA 2654408 C CA2654408 C CA 2654408C CA 2654408 A CA2654408 A CA 2654408A CA 2654408 A CA2654408 A CA 2654408A CA 2654408 C CA2654408 C CA 2654408C
- Authority
- CA
- Canada
- Prior art keywords
- subunit
- antibodies
- beta
- insulin receptor
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 17
- 201000010099 disease Diseases 0.000 title abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 10
- 208000002705 Glucose Intolerance Diseases 0.000 title abstract description 8
- 201000009104 prediabetes syndrome Diseases 0.000 title abstract description 8
- 239000003795 chemical substances by application Substances 0.000 title abstract description 3
- 238000010790 dilution Methods 0.000 claims abstract description 29
- 239000012895 dilution Substances 0.000 claims abstract description 29
- 102000003746 Insulin Receptor Human genes 0.000 claims abstract description 20
- 108010001127 Insulin Receptor Proteins 0.000 claims abstract description 20
- 230000001632 homeopathic effect Effects 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 239000007787 solid Substances 0.000 claims abstract description 7
- 239000000654 additive Substances 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 36
- 229940079593 drug Drugs 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 14
- 208000008589 Obesity Diseases 0.000 claims description 9
- 235000020824 obesity Nutrition 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 5
- 238000003825 pressing Methods 0.000 claims description 4
- 208000000059 Dyspnea Diseases 0.000 claims description 3
- 206010013975 Dyspnoeas Diseases 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- 206010022437 insomnia Diseases 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- 230000009471 action Effects 0.000 abstract description 5
- 238000013207 serial dilution Methods 0.000 abstract 2
- 238000007906 compression Methods 0.000 abstract 1
- 230000006835 compression Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 30
- 102000004877 Insulin Human genes 0.000 description 15
- 108090001061 Insulin Proteins 0.000 description 15
- 229940125396 insulin Drugs 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 229960004580 glibenclamide Drugs 0.000 description 5
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 5
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 102000047882 human INSR Human genes 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004900 c-terminal fragment Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 241000283707 Capra Species 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000000051 modifying effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2006119658/15A RU2437678C2 (ru) | 2006-06-06 | 2006-06-06 | Лекарственное средство для перорального лечения ожирения и способ получения твердой лекарственной формы для пероральной терапии ожирения |
| RU2006119655/15A RU2438707C2 (ru) | 2006-06-06 | 2006-06-06 | Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе |
| RU2006119658 | 2006-06-06 | ||
| RU2006119655 | 2006-06-06 | ||
| PCT/RU2007/000288 WO2007149010A1 (en) | 2006-06-06 | 2007-05-31 | Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2654408A1 CA2654408A1 (en) | 2007-12-27 |
| CA2654408C true CA2654408C (en) | 2018-05-08 |
Family
ID=38833657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2654408A Expired - Fee Related CA2654408C (en) | 2006-06-06 | 2007-05-31 | Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9308259B2 (enExample) |
| EP (2) | EP2036574A4 (enExample) |
| JP (1) | JP5687425B2 (enExample) |
| KR (1) | KR20090024241A (enExample) |
| AU (1) | AU2007261782A1 (enExample) |
| BR (1) | BRPI0712540A2 (enExample) |
| CA (1) | CA2654408C (enExample) |
| EA (1) | EA200802440A1 (enExample) |
| IL (2) | IL195755A (enExample) |
| MX (1) | MX2008015621A (enExample) |
| WO (1) | WO2007149010A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2181297C2 (ru) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| RU2309732C1 (ru) * | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
| MX2008015621A (es) | 2006-06-06 | 2009-03-06 | Oleg Iliich Epshtein | Agente medicinal para el tratamiento de obesidad, diabetes y enfermedades relacionadas con la tolerancia deteriorada de glucosa. |
| ES2537100T3 (es) | 2009-04-07 | 2015-06-02 | Roche Glycart Ag | Anticuerpos biespecíficos trivalentes |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8926976B2 (en) * | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
| CN102597775A (zh) | 2009-09-25 | 2012-07-18 | 佐马技术有限公司 | 筛选方法 |
| RU2610438C2 (ru) * | 2011-06-02 | 2017-02-10 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Способ лечения патологического синдрома и лекарственное средство центрального и периферического действия для лечения патологического синдрома |
| JP2013532182A (ja) | 2010-07-15 | 2013-08-15 | イリイチ・エプシテイン オレグ | 組み合わせ医薬組成物及び神経変性疾患に関連する疾患又は状態を治療する方法 |
| NZ606775A (en) * | 2010-07-15 | 2015-08-28 | Oleg Iliich Epshtein | Combination pharmaceutical composition and methods of treating genitourinary system disorders |
| SG187037A1 (en) * | 2010-07-15 | 2013-02-28 | Oleg Iliich Epshtein | Pharmaceutical compositions and methods of treatment |
| EA030566B1 (ru) | 2010-07-15 | 2018-08-31 | Олег Ильич ЭПШТЕЙН | Способ повышения терапевтической эффективности активированной-потенцированной формы антитела к эндогенной биомолекуле и фармацевтическая композиция |
| KR20180127515A (ko) * | 2010-07-21 | 2018-11-28 | 올레그 일리치 엡쉬테인 | 당뇨병 및 대사성 장애의 치료를 위한 제약학적 복합 조성물 및 방법들 |
| JP2013533269A (ja) * | 2010-07-21 | 2013-08-22 | イリイチ・エプシテイン オレグ | 組み合わせ医薬組成物及び呼吸器の疾患又は状態に関連する疾患及び状態を治療する方法 |
| EP2596019A2 (en) | 2010-07-21 | 2013-05-29 | Oleg Iliich Epshtein | A method of treating attention deficit hyperactivity disorder |
| US20130045237A1 (en) * | 2010-08-06 | 2013-02-21 | Oleg Iliich Epshtein | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases |
| BR112013019975A2 (pt) | 2011-02-28 | 2017-08-01 | Hoffmann La Roche | proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira" |
| CA2824824A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
| PT2691415T (pt) * | 2011-03-28 | 2018-10-19 | Ablynx Nv | Método para produção de formulações sólidas compreendendo domínios variáveis únicos de imunoglobulina |
| RU2013111961A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
| RU2013111962A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
| RU2016115866A (ru) | 2013-10-11 | 2017-11-16 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи |
| RU2603623C2 (ru) * | 2014-06-06 | 2016-11-27 | Олег Ильич Эпштейн | Ветеринарная композиция и способ улучшения жизнеспособности животных, стимуляции прироста живой массы млекопитающих и птиц, повышения эффективности иммунизации, профилактики и/или лечения инфекционных заболеваний (варианты) |
| JP6721590B2 (ja) | 2014-12-03 | 2020-07-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 多重特異性抗体 |
| CN114366802A (zh) * | 2015-04-22 | 2022-04-19 | 西达-赛奈医疗中心 | 用于治疗2型糖尿病的肠内递送的苦味寡肽 |
| CA2994841A1 (en) | 2015-08-06 | 2017-02-09 | Xoma (Us) Llc | Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia |
| WO2025171378A1 (en) | 2024-02-09 | 2025-08-14 | Rezolute, Inc. | Insulin receptor modulation for tumor associated hyperinsulinism |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4963367A (en) | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
| US4839341A (en) | 1984-05-29 | 1989-06-13 | Eli Lilly And Company | Stabilized insulin formulations |
| JPS61176534A (ja) * | 1985-01-30 | 1986-08-08 | Takashi Muramatsu | 避妊用剤 |
| US4761371A (en) | 1985-02-12 | 1988-08-02 | Genentech, Inc. | Insulin receptor |
| US6803452B2 (en) | 1991-02-26 | 2004-10-12 | New York University | RPTP-β antibodies |
| US5698195A (en) | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
| RU2007989C1 (ru) | 1991-11-12 | 1994-02-28 | Акционерное общество "Трейдис" | Способ габович подбора гомеопатических препаратов и их разовой дозы |
| DK140992D0 (da) | 1992-11-24 | 1992-11-24 | Ole Buchardt | Fremgangsmaade til frembringelse af antistoffer mod haptener og andre b-celle-antigener, antistoffer opnaaet ved fremgangsmaaden og anvendelse af disse antistoffer til fremstilling af vacciner, isaer til veterinaermedicinsk brug |
| US5879677A (en) | 1992-12-09 | 1999-03-09 | The Scripps Research Institute | Method for inhibition of cerebral tissue factor mediated reperfusion damage |
| RU2033784C1 (ru) | 1993-05-28 | 1995-04-30 | Индивидуальное частное предприятие "Диалог" | Устройство для репродуцирования гомеопатических и изопатических препаратов |
| IT1261849B (it) | 1993-09-02 | 1996-06-03 | Avantgarde Spa | Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici. |
| EP0652014A1 (en) | 1993-11-10 | 1995-05-10 | National Institute Of Immunology | Treatment of prostatic hypertrophy |
| US5861266A (en) | 1994-02-28 | 1999-01-19 | New York University | Treatment of diabetes mellitus and insulin receptor signal transduction |
| AU1812595A (en) | 1994-02-28 | 1995-09-11 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Cell lines for the identification of substances affecting insulin receptor mediated signal transduction |
| IL110035A0 (en) | 1994-06-16 | 1994-10-07 | Tapuach Natural Technologies 1 | Homeopathic formulations |
| RU2137483C1 (ru) | 1995-08-02 | 1999-09-20 | Божедомов Владимир Александрович | Способ лечения урогенитальной хламидийной, уреаплазменной и микоплазменной инфекции |
| IL125743A (en) | 1996-02-12 | 2003-09-17 | Epshtein Oleg Iliich | Medicinal preparation containing an active medical substance with homeopathic potentiation |
| US5726027A (en) * | 1996-03-08 | 1998-03-10 | The Regents Of The University Of California | Method for treatment of insulin resistance |
| GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| RU2114646C1 (ru) | 1996-09-30 | 1998-07-10 | Олег Ильич Эпштейн | Способ повышения защитных свойств организма при воздействии внешних физических факторов |
| RU2104032C1 (ru) | 1997-03-11 | 1998-02-10 | Общество с ограниченной ответственностью "Снежный барс" | Способ усиления лечебного эффекта лекарственных средств |
| RU2122858C1 (ru) | 1997-12-29 | 1998-12-10 | Яковлева Людмила Борисовна | Гомеопатическое лекарственное средство седативного действия "вернисон" |
| WO1999045934A1 (fr) | 1998-03-11 | 1999-09-16 | Grelan Pharmaceutical Co., Ltd. | Preparations entero-solubles effervescentes |
| RU2187334C2 (ru) | 1998-05-22 | 2002-08-20 | Эпштейн Олег Ильич | Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство |
| US6007824A (en) | 1998-07-09 | 1999-12-28 | Duckett; Melvin J. | Natural composition and method for the treatment of sexual dysfunction |
| RU2144370C1 (ru) | 1999-01-06 | 2000-01-20 | Титиева Наталья Михайловна | Гомеопатическое лекарственное средство для лечения гипертрофии предстательной железы |
| RU2161955C1 (ru) | 1999-07-16 | 2001-01-20 | Эпштейн Олег Ильич | Способ изменения физико-химических или физико-химических и биологических свойств вещества |
| RU2181297C2 (ru) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| WO2002039923A2 (en) | 2000-10-27 | 2002-05-23 | Wayne State University | Inhibition of alpha-2 hs glycoprotein (ahsg/fetuin) in obesity and insulin control of glucose homeostasis |
| RU2192882C1 (ru) | 2001-04-18 | 2002-11-20 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения |
| RU2199345C1 (ru) | 2001-12-26 | 2003-02-27 | Эпштейн Олег Ильич | Лекарственное средство и способ регуляции углеводного и жирового обмена |
| AUPS019802A0 (en) * | 2002-01-31 | 2002-02-21 | Chemstop Pty Ltd | Nutrient formulation |
| WO2004012765A1 (fr) | 2002-08-02 | 2004-02-12 | Oleg Iliich Epshtein | Preparation medicinale et procede de traitement d'un syndrome pathologique determine par une perturbation de l'hematopoiese |
| UA76638C2 (en) | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
| UA76639C2 (uk) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій |
| UA76641C2 (uk) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози |
| RU2253478C1 (ru) | 2003-10-01 | 2005-06-10 | Эпштейн Олег Ильич | Средство для потенцирования лечебных эффектов - усиления действия лекарственного вещества |
| RU2309732C1 (ru) | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
| MX2008015621A (es) | 2006-06-06 | 2009-03-06 | Oleg Iliich Epshtein | Agente medicinal para el tratamiento de obesidad, diabetes y enfermedades relacionadas con la tolerancia deteriorada de glucosa. |
| KR20180127515A (ko) * | 2010-07-21 | 2018-11-28 | 올레그 일리치 엡쉬테인 | 당뇨병 및 대사성 장애의 치료를 위한 제약학적 복합 조성물 및 방법들 |
-
2007
- 2007-05-31 MX MX2008015621A patent/MX2008015621A/es not_active Application Discontinuation
- 2007-05-31 CA CA2654408A patent/CA2654408C/en not_active Expired - Fee Related
- 2007-05-31 WO PCT/RU2007/000288 patent/WO2007149010A1/ru not_active Ceased
- 2007-05-31 US US12/303,648 patent/US9308259B2/en not_active Expired - Fee Related
- 2007-05-31 KR KR1020097000197A patent/KR20090024241A/ko not_active Withdrawn
- 2007-05-31 JP JP2009514226A patent/JP5687425B2/ja not_active Expired - Fee Related
- 2007-05-31 EP EP07794025A patent/EP2036574A4/en not_active Withdrawn
- 2007-05-31 EA EA200802440A patent/EA200802440A1/ru unknown
- 2007-05-31 EP EP11007331A patent/EP2395021A1/en not_active Withdrawn
- 2007-05-31 BR BRPI0712540-2A patent/BRPI0712540A2/pt not_active Application Discontinuation
- 2007-05-31 AU AU2007261782A patent/AU2007261782A1/en not_active Abandoned
-
2008
- 2008-12-07 IL IL195755A patent/IL195755A/en active IP Right Grant
-
2016
- 2016-02-11 US US15/041,582 patent/US20160159916A1/en not_active Abandoned
- 2016-06-22 IL IL246402A patent/IL246402A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP5687425B2 (ja) | 2015-03-18 |
| US20160159916A1 (en) | 2016-06-09 |
| BRPI0712540A2 (pt) | 2012-10-16 |
| EA200802440A1 (ru) | 2009-06-30 |
| US9308259B2 (en) | 2016-04-12 |
| KR20090024241A (ko) | 2009-03-06 |
| US20110008452A1 (en) | 2011-01-13 |
| MX2008015621A (es) | 2009-03-06 |
| IL246402A (en) | 2017-12-31 |
| JP2009539827A (ja) | 2009-11-19 |
| IL195755A (en) | 2016-07-31 |
| AU2007261782A1 (en) | 2007-12-27 |
| CA2654408A1 (en) | 2007-12-27 |
| EP2036574A4 (en) | 2009-07-01 |
| WO2007149010A1 (en) | 2007-12-27 |
| EP2036574A1 (en) | 2009-03-18 |
| IL195755A0 (en) | 2011-08-01 |
| EP2395021A1 (en) | 2011-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2654408C (en) | Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance | |
| AU2006340119B2 (en) | Solid oral form of a medicinal preparation and a method for the production thereof | |
| AU2011287292B2 (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| US20100209430A1 (en) | Method for treating erectile dysfunction | |
| US20070141058A1 (en) | Method of correcting immunopathological reactions and a medicament | |
| SE1350212A1 (sv) | Farmaceutisk kombinationskomposition och meto der för behandling av diabetes och metabola rubbningar | |
| US20120294899A1 (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
| AU2011281247A1 (en) | Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition | |
| CN101495143A (zh) | 用于治疗肥胖、糖尿病和与受损的葡萄糖耐受性有关的疾病的药物制剂 | |
| CA2804969A1 (en) | A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system | |
| RU2437678C2 (ru) | Лекарственное средство для перорального лечения ожирения и способ получения твердой лекарственной формы для пероральной терапии ожирения | |
| RU2543332C2 (ru) | Лекарственное средство для коррекции эндотелиальной дисфункции | |
| RU2441023C1 (ru) | Лекарственное средство для лечения рассеянного склероза и способ лечения рассеянного склероза | |
| WO2015189709A2 (en) | Veterinary composition and method of improving livability of animals, promoting live weight gain in mammals and birds, enhancing the effectiveness of immunization, and preventing and/or treating infectious diseases | |
| CA2807529A1 (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20220301 |
|
| MKLA | Lapsed |
Effective date: 20200831 |